Raymond James & Associates raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 131.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,916 shares of the medical equipment provider’s stock after acquiring an additional 15,830 shares during the quarter. Raymond James & Associates’ holdings in Lantheus were worth $1,963,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently modified their holdings of the stock. FinTrust Capital Advisors LLC acquired a new stake in shares of Lantheus in the second quarter valued at approximately $26,000. Dupont Capital Management Corp bought a new stake in shares of Lantheus during the second quarter worth $32,000. Focused Wealth Management Inc acquired a new position in shares of Lantheus during the third quarter valued at $63,000. Financial Gravity Asset Management Inc. bought a new position in Lantheus in the second quarter valued at about $2,319,000. Finally, Spire Wealth Management acquired a new stake in Lantheus in the second quarter worth about $119,000. 97.62% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on LNTH. Jonestrading started coverage on shares of Lantheus in a research note on Thursday, October 6th. They issued a “buy” rating and a $104.00 target price on the stock. SVB Leerink assumed coverage on shares of Lantheus in a report on Wednesday, November 30th. They set an “outperform” rating for the company. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Friday, November 4th. Finally, Mizuho started coverage on Lantheus in a research report on Wednesday, October 12th. They issued a “buy” rating and a $105.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $102.80.
Lantheus Stock Up 2.2 %
Lantheus (NASDAQ:LNTH – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The medical equipment provider reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.15. The business had revenue of $239.29 million during the quarter, compared to analysts’ expectations of $228.52 million. Lantheus had a net margin of 13.35% and a return on equity of 37.77%. Analysts forecast that Lantheus Holdings, Inc. will post 3.53 earnings per share for the current year.
Insider Transactions at Lantheus
In related news, COO Paul Blanchfield sold 2,432 shares of the stock in a transaction that occurred on Thursday, November 17th. The stock was sold at an average price of $54.79, for a total transaction of $133,249.28. Following the completion of the sale, the chief operating officer now directly owns 73,968 shares of the company’s stock, valued at approximately $4,052,706.72. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, COO Paul Blanchfield sold 2,432 shares of the stock in a transaction on Thursday, November 17th. The shares were sold at an average price of $54.79, for a total transaction of $133,249.28. Following the completion of the sale, the chief operating officer now owns 73,968 shares of the company’s stock, valued at $4,052,706.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Daniel Niedzwiecki sold 3,000 shares of the firm’s stock in a transaction on Friday, November 11th. The stock was sold at an average price of $59.73, for a total transaction of $179,190.00. Following the sale, the insider now owns 65,143 shares in the company, valued at $3,890,991.39. The disclosure for this sale can be found here. Insiders have sold a total of 19,354 shares of company stock valued at $1,105,945 over the last 90 days. 1.60% of the stock is owned by company insiders.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.